Anti-Human TNFRSF10A Recombinant Antibody (Mapatumumab) (CAT#: TAB-H48)
Recombinant human antibody to Human TNFRSF10A. Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody for the treatment of cancer.
Specific Inquiry
Figure 1 Mapatumumab and etoposide synergize to induce apoptosis through the mediation of NF-jB.
(A) Inhibition of NF-jB disrupts synergy between Mapatumumab and etoposide. HT29 cells were untreated, treated with 100 lM etoposide, 10 lM BAY 11-7082, or 100 ug/ml of Mapatumumab alone or in combination. 48 h after treatment cells were collected and cell death was assessed by acridine orange staining. Error bars represent the standard deviation of three independent experiments. Statistical significance was calculated using a Student's t test. (B) Combination treatment between Mapatumumab and Etoposide increases DNA fragmentation; this is disrupted by NFjB blockage. Cells were treated with 100 uM etoposide, 10 lM BAY 11-7082, 100 ug/ml of Mapatumumab, or 20 uM of z-VAD-FMK alone or in combination. 48 h after transfection cells were collected and stained with propidium iodide staining buffer.
Mendoza, F. J., Ishdorj, G., Hu, X., & Gibson, S. B. (2008). Death receptor-4 (DR4) expression is regulated by transcription factor NF-κB in response to etoposide treatment. Apoptosis, 13(6), 756.
Figure 2 Cleaved caspase-8 was associated with DR4 or DR5 in relation to mapatumumab or lexatumumab sensitivity.
Immunoprecipitation (IP) assays of mapatumumab (Mapa) or lexatumumab (Lexa) were conducted in LP1, MDN, and NCI-H929 cells. Cells (20 × 106) were incubated with or without (control) 10 μg/mL of mapatumumab (45 minutes) or lexatumumab (90 minutes) at 37°C in RPMI-1640 containing 5% FCS. For NCI-H929, cells were pretreated for 2 hours with 2.5μmol/L nutlin-3a (N) before addition of lexatumumab. The lysates were immunoprecipitated with a mix of proteins A and G (2 mg of lysate proteins were immunoprecipitated in each assay). For untreated cells, IP was conducted after addition of mapatumumab or lexatumumab to the lysates. The immunoprecipitates were analyzed for the presence of the indicated proteins by immunoblot (IB) analysis. Input, lysates of untreated or treated cells; Ct Ip< IP of control lysates (untreated cells); Ip< IP of lysates obtained from cells treated with mapatumumab or lexatumumab. *, heavy chain of mapatumumab or lexatumumab.
Surget, S., Chiron, D., Gomez-Bougie, P., Descamps, G., Ménoret, E., Bataille, R., ... & Pellat-Deceunynck, C. (2012). Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer research, canres-0487.
Specifications
- Host Species
- human
- Derivation
- human
- Type
- IgG1
- Specificity
- TNFRSF10A(tumor necrosis factor receptor (TNFR) superfamily member 10A, death receptor 4, DR4, TNF-related apoptosis-inducing ligand receptor 1, TRAILR1, TRAIL-R1, TR-1, CD261) agonistic antibody [Homo sapiens]
- Species Reactivity
- Human
- Applications
- Neut, ELISA, IF, IP, FuncS, FC, IHC
- CAS
- 658052-09-6
- Generic Name
- mapatumumab
- MW
- 151.89 kDa
- Related Disease
- Colorectal cancers
Product Property
- Purity
- >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Applications
- Application Notes
- The TNFRSF10A antibody has been reported in applications of FC, IP.
Target
- Alternative Names
- mapatumumab;658052-09-6;HGS-ETR1;TRM-1;HGS-ETR1;HGS-ETR1;TNFRSF10A;tumor necrosis factor receptor superfamily, member 10a;tumor necrosis factor receptor superfamily member 10A;Apo2;CD261;DR4;TRAILR 1;TRAIL-R1;TRAIL receptor 1;death receptor 4;cytotoxic TR
- Gene ID
- 8797
- UniProt ID
- O00220
Related Resources
Please refer to Mapatumumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Mapatumumab.
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Mapatumumab"
Afuco™ Anti-TNFRSF10A ADCC Recombinant Antibody (Mapatumumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human antibody to Human TNFRSF10A. Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody for the treatment of cancer.
See other products for "TNFRSF10A"
Select a product category from the dropdown menu below to view related products.
Please select product type
Recombinant Antibody
Human Antibody
Mouse Antibody
Neutralizing Antibody
Rabbit Monoclonal Antibody
Single-domain Antibody
scFv Fragment Antibody
ADCC Enhanced Antibody
Fab Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-1242z | Mouse Anti-TNFRSF10A Recombinant Antibody (clone 27A12) | WB, FC, IHC, Neut | Mouse IgG1 |
| FN-011CQ | Mouse Anti-TNFRSF10A Recombinant Antibody (clone HS101) | FC, Inhib, ICC, IP | Mouse IgG1 |
| HPAB-1616-FY | Mouse Anti-TNFRSF10A Recombinant Antibody (clone mAY4) | ELISA, SPR, Cyt, Inhib | Mouse IgG |
| HPAB-1617-FY | Human Anti-TNFRSF10A Recombinant Antibody (clone hAY4) | PP, ELISA, SPR, Cyt | Humanized IgG |
| HPAB-1618-FY | Human Anti-TNFRSF10A Recombinant Antibody (clone Hvh3) | WB, ELISA | Human IgG |
Customer Reviews and Q&As
Customer Review
Q&As
-
Ideal for TNFRSF10A Research
The Anti-Human TNFRSF10A Therapeutic Antibody (mapatumumab) has been excellent for our TNFRSF10A research. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time. -
Effective in Immunoassays
We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for TNFRSF10A is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab. -
Consistent and Reliable
This antibody has proven to be consistent and reliable in our assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for TNFRSF10A have been particularly beneficial.
Popular products with customers
Application: WB, IP, IF, FuncS, FC, Neut, ELISA
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: ELISA, IP, FC, FuncS, Neut, IF, ICC
Application: WB, IHC, FC, Cyt, ELISA
Application: WB, ELISA, FuncS
Application: WB, ELISA, FuncS
![Figure 1 Anti-Human CD19 Recombinant Antibody Fab Fragment [TAB-1611CL-F(E)] in SDS-PAGE](https://img.creativebiolabs.net/productimages/COA-TAB-1611CL-F(E)-1.png)
Application: Depletion, FuncS
Application: ELISA, FuncS, IHC, IF, FC, ADCC
Application: FC, IA, IF, IP, IHC, FuncS
Application: Inhib, ELISA, FC, FuncS
-1.jpg)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
